The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
Open accessAbstract
INTRODUCTION: Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI). Durvalumab is an anti-programmed death ligand 1 monoclonal antibody. The phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and EGFR T790M mutation-positive advanced NSCLC and disease progression after EGFR-TKI therapy. METHODS: Patients were randomly assigned 1:1 to receive orally administered osimertinib (80 mg once daily) with or without durvalumab (10 mg/kg administered intravenously every 2 weeks) until progression. Treatment could continue beyond progression, providing clinical benefit continued (judged by the investigator). The amended primary objective was to assess the safety and tolerability of osimertinib plus durvalumab; efficacy was an exploratory objective. RESULTS: CAURAL recruitment was terminated early because of increased incidence of interstitial lung disease-like events in the osimertinib plus durvalumab arm from the separate phase Ib TATTON trial (NCT02143466). At termination of CAURAL recruitment, 15 patients had been randomly assigned to treatment with osimertinib and 14 to treatment with osimertinib plus durvalumab. The most common AEs were diarrhea (53% [grade ≥3 in 6% of patients]) in the osimertinib arm and rash (67% [grade ≥3 in 0 patients]) in the combination arm. One patient who had been randomized to the combination arm reported grade 2 interstitial lung disease while receiving osimertinib monotherapy (after discontinuing durvalumab therapy after one dose). The objective response rates were 80% in the osimertinib arm and 64% in the combination arm. CONCLUSION: Limited patient numbers preclude formal safety and efficacy comparisons between the two treatment arms. The combination of programmed cell death 1/programmed death ligand 1 inhibitors and EGFR-TKIs as therapy for NSCLC is not well understood, but it requires a careful approach if considered in the future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because of the increased risk of treatment-associated interstitial lung disease, a phase 3 clinical trial CAURAL was stopped early [193].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [193]
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationOsimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250
Zhang, Y., Yuan, J.-Q., Wang, K., Fu, X., Han, X., Threapleton, D. E., Yang, Z., Mao, C., & Tang, J.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.12587 · Cited by 866
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Self-citationChen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 681
Hanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I., Leighl, N. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6065 · Cited by 643
Cited by
Sorted by citations
Items 201–210 of 210
Tao, R., Lin, I., Chen, C., & Du, S. (2025) · Cureus · doi:10.7759/cureus.97347
Huang, H., Zhu, X., Yu, Y., Li, Z., Yang, Y., Xia, L., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26301137
Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity
Yokomura, M., Nagano, S., Kawamoto, H., Hirohashi, Y., Torigoe, T., Asakage, T., & Katayama, R. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04279-7
Osimertinib for Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Current Evidence
Tang, X., Chen, Y., Zhu, Y., Liu, Y., Li, W., Wang, W., & Wang, Z. (2026) · Clinical Medicine Insights Oncology · doi:10.1177/11795549261434260
Bai, M., Gao, Q., Jin, P., Ma, L., Li, J., Wu, L., Wang, W., Lv, L., Li, Y., Cheng, B., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02653-2
Liu, W.-H., Cheng, Y.-J., Kang, J., Chen, J., An, Z.-J., Li, T.-H., Tan, N., Zhong, W., Wu, Y.-L., & Jiang, L. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109413
He, X. L., Tian, T., Ma, Y., Cai, Q., Deng, G., Zhang, X., & Liang, N. (2026) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1981_25
Yu, D., Liu, H., Zhang, J., Li, X. T., Yu, Y., & Lyu, H. (2026) · Journal of Cardio-oncology · doi:10.1097/co9.0000000000000021
The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective
Waissengrin, B., Tagliamento, M., Sankar, K. N., & Reckamp, K. L. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103957
p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications
Etessami, J. D., Attili, I., Aliaga, P. T., Cavallone, M., Giordano, E., Napoli, V. M., Signore, E. D., Spitaleri, G., Curigliano, G., & Passaro, A. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103212
Metadata
- Authors
- Yang, J. C.-H., Shepherd, F. A., Kim, D.-W., Lee, G.-W., Lee, J. S., Chang, G.-C., Lee, S. S., Wei, Y.-F., Lee, Y. G., Laus, G., Collins, B., Pisetzky, F., & Horn, L.
- Affiliations
- National Taiwan University Hospital (TW)
- University of Toronto (CA)
- Seoul National University (KR)
- Gyeongsang National University (KR)
- Taichung Veterans General Hospital (TW)
- Inje University (KR)
- E-Da Hospital (TW)
- Kangbuk Samsung Hospital (KR)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Netherlands) (NL)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Yang, James Chih-Hsin
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 14
- Issue
- 5
- Pages
- 933-939
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2912107322
- Cited by
- 210
- References
- 17
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 39 · 2021: 42 · 2020: 27 · 2019: 13
- FWCI
- 22.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Meso Scale Diagnostics
- Takeda Pharmaceuticals North America
- AstraZeneca
- EMD Serono (NCT02454933)
- Bayer
- Celgene
- Eli Lilly and Company
- Daiichi Sankyo Company
- AbbVie
- Bristol-Myers Squibb
- Pfizer
- Novartis
- Astellas Pharma Canada
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- osimertinib, durvalumab, T790M mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitor resistance, immune checkpoint inhibitors, interstitial lung disease, safety and tolerability, combination therapy
- MeSH terms
- Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Pyrimidines, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
